Corona in general

Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history The study also showed that prior exposure to SARS-CoV-2 does not guarantee a high level of antibodies, nor does it guarantee a robust antibody response to the first vaccine dose. This directly contradicts the assumption that contracting COVID will naturally make someone immune to re-infection. The findings further support vaccination (and two doses), even for people who have contracted the virus previously. // 30.8.2021

A team of scientists from the United States has recently examined the trajectory of early immune biomarkers in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. They have identified specific plasma proteins that can accurately predict the clinical and virological outcomes in SARS-CoV-2 infected patients. // 31.8.2021

A buildup of coronavirus in the lungs is likely behind the steep mortality rates seen in the pandemic, a new study finds.// 31.8.2021

Certain regions of the SARS-CoV-2 genome might be a suitable target for future drugs. This is what researchers at Goethe University, together with their collaborators in the international COVID-19-NMR consortium, have now discovered. //31.8.2021

More coronavirus RNA is in fine aerosols than in larger droplets, but masks can reduce the amount of virus in the air.// 31.8.2021

Nature - The self-targeting antibodies attack type 1 interferons that play a key role in fighting infection.// 31.8.2021

Good evening. I'm Karen Kaplan, and it’s Tuesday, Aug. 31. //31.8.2021

A new study finds that people with SARS-CoV-2 were most likely to transmit the virus between 2 days before and 3 days after symptom onset.// 31.8.2021

Nature Microbiology - Proviral host factors for SARS-CoV-2 infection, cellular processes that are important in SARS-CoV-2 replication and host factors that could be targeted by antiviral therapies...// 1.9.2021

Nature Communications - In this study, Marlin et al. provide insights into the potential use of subunit vaccines that induce a high level of protection against SARS-CoV-2 in animal models.// 1.9.2021

A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.// 3.9.2021

A new study provides evidence of the correlation and estimated the period between the generation interval and incubation period of SARS-CoV-2.// 5.9.2021

Researchers in Australia and Finland have provided important insights into how infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – might affect nervous system circuitries and cause neurologic symptoms.// 6.9.2021

Can people become immune to SARS-CoV-2? Read on to learn more about immunity to the virus, such as how to acquire it and how long it may last.// 7.9.2021

The presence of special immune system defense molecules, called autoimmune antibodies, has been strongly tied to how poorly people fare when hospitalized with COVID-19, a new study shows.// 9.9.2021

A group of researchers analyzed the B cell response to SARS-CoV-2 in unexposed individuals.// 10.9.2021

A COVID-19 vaccine, created from a virus-like nanoparticle that displays SARS-CoV-2 spike protein RBDs, effectively protects animal model from infection.// 10.9.2021

As COVID-19 cases continue to skyrocket across the U.S. and the world, few options are available for treating patients infected with the SARS-CoV-2.// 11.9.2021

A recent study, currently available on the bioRxiv* preprint server, reveals that a specific region of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be targeted by antisense oligonucleotides to potently inhibit viral replication, and consequently the development of coronavirus disease (COVID-19).// 12.9.2021

A new study published in the journal Frontiers of Medicine indicated that Barrett's esophagus (BE) and gastroesophageal reflux disease (GERD) may represent novel comorbidities associated with SARS-CoV-2 disease. A previous study had estimated that in the United States, 5.6% of adults have BE, a disease where esophageal squamous mucosa gets damaged by GERD.// 12.9.2021

Like many US states, Texas introduced many different measures to reduce the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as masking, social distancing, and the closure of public services and businesses likely to aid the spread of disease.// 13.9.2021

Now, a new study published on the bioRxiv* preprint server investigates this relationship further and suggests that current smoking is not associated with a higher incidence of SARS-CoV-2 infection.//13.9.2021

Scientists were inspired by the robust serum nAb responses in people who recovered from natural SARS-CoV-2 infection and were later vaccinated using mRNA vaccine. They isolated and characterized bnAbs from two COVID-19 convalescent donors who were recently vaccinated. These isolated bnAbs were found to be highly potent against sarbecoviruses. //13.9.2021

Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).// 14.9.2021

In a new study posted to the medRxiv* server scientists from Weil Cornell University and Stony Brook University in New York attempted to identify the metabolic and immune markers associated with severe COVID-19 disease using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. This will facilitate risk stratification, monitoring, and therapeutic interventions in COVID-19 patients. //14.9.2021

Asymptomatic individuals carrying SARS-CoV-2 can transmit the virus and contribute to outbreaks of COVID-19, but it is not yet clear how the proportion of asymptomatic infections varies by age and geographic location./ 14.9.2021

In a research paper recently uploaded to the medRxiv* preprint server by Capelle et al. (September 2nd, 2021), the immune response of mild and hospitalized COVID-19 patients is compared, finding that early T-cell response is a vital indicator of SARS-CoV-2 disease severity. //15.9.2021

Researchers decided to investigate how effective immunity gained from previous SARS-CoV-2 infection protects a wider community from disease.// 15.9.2021

Now, researchers at the Garvan Institute of Medical Research, Darlinghurst in Australia, CSIRO Data61, and the School of Biotechnology and Biomolecular Sciences (UNSW) demonstrated the most comprehensive analysis of the three-dimensional structure of SARS-CoV-2, providing a new insight into how the virus infects cells and replicates.// 6.9.2021